A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
AstraZeneca
Coherus Oncology, Inc.
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Novartis
InSilico Medicine Hong Kong Limited
AstraZeneca
BeiGene
Eli Lilly and Company
ALX Oncology Inc.
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Imugene Limited
Checkpoint Therapeutics, Inc.
Genentech, Inc.
Taiho Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Altor BioScience
Nektar Therapeutics
Pfizer
Eli Lilly and Company
AbbVie
AstraZeneca
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Amgen
AstraZeneca
CanBas Co. Ltd.
Altor BioScience
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
Amgen
Sanofi
Zivena